Inhibitory effect of orally administered donepezil hydrochloride (E2020), a novel treatment for Alzheimer's disease, on cholinesterase activity in rats

European Journal of Pharmacology

Volumn 389, Issue 2-3, 2000, Pages 173-179

  Kosasa, Takashi ^a   Kuriya, Yuka ^a   Matsui, Kenji ^a   Yamanishi, Yoshiharu ^a  

^a EISAI CO LTD   (Japan)

Author keywords

Cholinesterase; Cholinesterase inhibitor; Donepezil hydrochloride (E2020); ENA 713; NIK 247; Physostigmine; Tacrine; TAK 147

Indexed keywords

ACETYLCHOLINESTERASE; DONEPEZIL; RIVASTIGMINE; TACRINE; ZANEPEZIL;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFECT; DRUG PENETRATION; ENZYME INHIBITION; MALE; NONHUMAN; PLASMA; PRIORITY JOURNAL; RAT;

ADMINISTRATION, ORAL; ALZHEIMER DISEASE; ANIMALS; BENZAZEPINES; BRAIN; CARBAMATES; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; INDANS; LEARNING; MALE; MEMORY; PHENYLCARBAMATES; PIPERIDINES; RATS; RATS, WISTAR; TACRINE;

EID: 0034681325     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00876-6     Document Type: Article

References (29)

1. Adler M., Filbert M.G. Role of butyrylcholinesterase in canine tracheal smooth muscle function. FEBS Lett. 167:1990;107-110.
2. Anand R., Gharabawi G. Clinical development of exelon (ENA-713): the Adena programme. J. Drug Dev. Clin. Pract. 8:1996;9-14.
3. Bowen D.M., Smith C.B., White P., Davison A.N. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain. 99:1976;459-496.
4. Chatonnet A., Lockridge O. Comparison of butyrylcholinesterase and acetylcholinesterase. Biochem. J. 260:1989;625-634.
5. Davis P., Maloney A.J.F. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet. 2:1976;1403.
6. Dawson K.L. Reversibility of the inhibition of acetylcholinesterase by tacrine. Neurosci. Lett. 100:1990;227-230.
7. Drachman D.A. Memory and cognitive function in man: does the cholinergic system have a specific role? Neurology. 27:1977;783-790.
8. Edwards J.A., Brimijoin S. Divergent regulation of acetylcholinesterase and butyrylcholinesterase in tissues of the rat. J. Neurochem. 38:1982;1393-1403.
9. Ellman G.L., Courtney K.D., Anders V., Featherstone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7:1961;88-95.
10. Enz A., Amstutz R., Boddeke H., Gmelin G., Malanowski J. Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease. Prog. Brain Res. 98:1993;431-438.
11. Hirai K., Kato K., Nakayama T., Hayako H., Ishihara Y., Goto G., Miyamoto M. Neurochemical effects of 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-1-propanone fumarate (TAK-147), a novel acetylcholinesterase inhibitor, in rats. J. Pharmacol. Exp. Ther. 280:1997;1261-1269.
12. Hunter A.J., Murray T.K., Jones J.A., Cross A.J., Green A.R. The cholinergic pharmacology of tetrahydroaminoacridine in vivo and in vitro. Br. J. Pharmacol. 98:1989;79-86.
13. Kosasa T., Kuriya Y., Matsui K., Yamanishi Y. Effect of donepezil hydrochloride (E2020) on basal concentration of extracellular acetylcholine in the hippocampus of rats. Eur. J. Pharmacol. 380:1999;101-107.
14. Kosasa T., Kuriya Y., Yamanishi Y. Effect of donepezil hydrochloride (E2020) on extracellular acetylcholine concentration in the cerebral cortex of rats. Jpn. J. Pharmacol. 81:1999;216-222.
15. Massoulié J., Pezzementi L., Bon S., Krejci E., Vallette F.M. Molecular and cellular biology of cholinesterase. Prog. Neurobiol. 41:1993;31-91.
16. Miyamoto M., Takahashi H., Kato K., Hirai K., Ishihara Y., Goto G. Effects of 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-1-propanone fumarate (TAK-147), a novel acetylcholinesterase inhibitor, on impaired learning and memory in animal models. J. Pharmacol. Exp. Ther. 277:1996;1292-1304.
17. Perry E.K., Gibson P.H., Blessed G., Perry R.H., Tomlinson B.E. Neurotransmitter enzyme abnormalities in senile dementia: choline acetyltransferase and glutamic acid decarboxylase in necropsy brain tissue. J. Neurol. Sci. 34:1977;247-265.
18. Perry E.K., Tomlinson B.E., Blessed G., Bergman K., Gibson P.H., Perry R.H. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br. Med. J. 2:1978;1456-1459.
19. Rogers S.L., Doody R.S., Mohs R., Friedhoff L.T. Donepezil Study Group Donepezil improves cognitive and global function in Alzheimer's disease: a 15-week double-blind, placebo-controlled study. Arch. Intern. Med. 158:1998;1021-1031.
20. Rogers S.L., Farlow M.R., Doody R.S., Mohs R., Friedhoff L.T. Donepezil Study Group A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology. 50:1998;136-145.
21. Rogers S.L., Friedhoff L.T. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicenter open label extension study. Eur. Neuropsychopharmacol. 8:1998;67-75.
22. Rogers S.L., Friedhoff L.T. Donepezil Study Group The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicenter, randomized, double-blind, placebo-controlled trial. Dementia. 7:1996;293-303.
23. Rogers S.L., Yamanishi Y., Yamatsu K. E2020: the pharmacology of a piperidine cholinesterase inhibitor. Becker R., Giacobini E. Cholinergic Basis for Alzheimer Therapy. 1991;314-320 Birkhäuser, Boston, MA.
24. Sherman K.A. Pharmacodynamics of oral E2020 and tacrine in humans: novel approaches. Becker R., Giacobini E. Cholinergic Basis for Alzheimer Therapy. 1991;321-328 Birkhäuser, Boston, MA.
25. Sugimoto H., Iimura Y., Yamanishi Y., Yamatsu K. Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine hydrochloride and related compounds. J. Med. Chem. 38:1995;4821-4829.
26. Thomsen T., Kewitz H., Pleul O. A suitable method to monitor inhibition of cholinesterase activities in tissues as induced by reversible enzyme inhibitors. Enzyme. 42:1989;219-224.
27. Traina M.E., Serpietri L.A. Changes in the levels and forms of rat plasma cholinesterases during chronic diisopropylphosphorofluoridate intoxication. Biochem. Pharmacol. 33:1984;645-653.
28. Weinstock M., Razin M., Chorev M., Enz A. Pharmacological evaluation of phenyl-carbamates as CNS-selective acetylcholinesterase inhibitors. J. Neural Transm. 43:1994;219-225.
29. Whitehouse P.J., Price D.R., Struble R.G., Clark A.W., Coyle J.T., Delong M.R. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science. 215:1982;1237-1239.